Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $6.67 Consensus Price Target from Analysts

Gossamer Bio, Inc. (NASDAQ:GOSS) has earned an average rating of “Hold” from the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $5.4286.

A number of equities research analysts have commented on the stock. Royal Bank Of Canada raised shares of Gossamer Bio to an “outperform” rating in a report on Tuesday, February 24th. Wedbush reissued a “neutral” rating and set a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a research note on Tuesday, February 24th. The Goldman Sachs Group lowered shares of Gossamer Bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Gossamer Bio in a report on Thursday, January 22nd. Finally, Leerink Partners cut Gossamer Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $0.50 on Wednesday. Gossamer Bio has a 52 week low of $0.33 and a 52 week high of $3.87. The stock has a market capitalization of $115.89 million, a PE ratio of -0.73 and a beta of 2.08. The stock’s fifty day moving average is $2.12 and its 200-day moving average is $2.58.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of GOSS. Legal & General Group Plc bought a new stake in shares of Gossamer Bio during the second quarter worth approximately $26,000. Ciovacco Capital Management LLC bought a new stake in shares of Gossamer Bio during the 3rd quarter valued at $27,000. Banco BTG Pactual S.A. acquired a new position in shares of Gossamer Bio in the 2nd quarter valued at $27,000. MMA Asset Management LLC bought a new position in shares of Gossamer Bio in the 4th quarter worth $31,000. Finally, Soltis Investment Advisors LLC bought a new stake in Gossamer Bio in the fourth quarter valued at about $31,000. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.